Breathe Well Live Well
BioPharma-Reporter.com |
Asthma: It's a mAb, mAb, mAb, mAb world says analyst
BioPharma-Reporter.com News that Sanofi and Regeneron's mAb alirocumab has lower cardiovascular risks than other cholesterol drugs may have grabbed recent headlines, but it is their asthma candidate, dupilumab , that has caught the eye of GlobalData analyst, Valentina … |
View full post on asthma – Google News
|
KaloBios to Stop KB003 Development for Asthma – Analyst Blog
NASDAQ KaloBios Pharmaceuticals, Inc. ( KBIO ) announced disappointing top line results from a phase II study on KB003 in patients suffering from severe asthma, where the candidate failed to meet the key endpoints. We expect the news to have a significant … KaloBios shares tank on failed asthma drug trial KaloBios calls it quits on its asthma drug after a Phase II flop KaloBios Pharma pulls plug on asthma drug, shares plunge |
View full post on asthma – Google News
|
Dupilumab Could End of Being 'Blockbuster' Asthma Drug – Analyst (SNY) (REGN)
StreetInsider.com (subscription) Dupilumab may debut in 2018 as a treatment for skin and/or asthma conditions, Fernandez said. He observes the large market for asthma, with competition expected from the likes of AstraZenece (NYSE: AZN), GlaxoSmithKline (NYSE: GSK), and others. |
View full post on asthma – Google News
|
Positive Data on MediciNova's MN-221 – Analyst Blog
NASDAQ MediciNova is developing MN-221, a highly selective beta(2)-adrenergic receptor agonist, for the treatment of acute exacerbations of asthma and COPD. In 2004, MediciNova licensed exclusive rights to MN-221 from Kissei Pharmaceutical Co., Ltd. in all … Drug trial signals hope for asthma sufferers MediciNova Announces Positive Preliminary Results From a Multi-Day, Repeat … Illinois Investor Commits to Buy MediciNova Stock |
View full post on asthma – Google News
 InPharm |
Pipeline Progresses at Glaxo/THRX – Analyst Blog
NASDAQ The companies also completed the phase III Breo registrational program for the treatment of persistent asthma in adults and adolescents. Positive results were reported from a study evaluating the efficacy and safety of fluticasone furoate and … GSK and Theravance file for FF/VI approval in the USA and Europe; Talks with … GSK, Theravance seek approvals for FF/VI in US, Europe GSK and Theravance file COPD drug |
View full post on asthma – Google News